Inspyr Therapeutics Inc is a biopharmaceutical company specializing in the development of therapies for cancer, inflammation, and other diseases. Established in 2003, the company's focus lies in adenosine chemistry and biology, driving its product pipeline, which includes Mipsagargin for various tumor types such as Hepatocellular carcinoma (liver cancer), Glioblastoma (brain cancer), and Prostate cancer. Additionally, it is developing combination treatments, including PD1/PDL1 combination and Xenograft models. With its last investment of $500.00KPost-IPO Debt investment on 12 January 2021, the company showcases potential in the Biotechnology and Health Care industries. Although specific headquarters are not disclosed, the company's innovative approach to adenosine receptor programs positions it as an intriguing prospect for potential investors in the health and wellness sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $500.00K | - | 12 Jan 2021 | |
| Post-IPO Equity | $2.51M | - | 27 Jul 2015 | |
| Post-IPO Equity | $280.00K | - | 06 Dec 2014 | |
| Post-IPO Equity | $773.00K | - | 30 Jun 2014 | |
| Post-IPO Equity | $5.00M | - | 19 Aug 2013 |
No recent news or press coverage available for Inspyr Therapeutics Inc.
We care about your data, and we'd love to use cookies make your experience better.
